Member Info for draft

as u know I know a few radiologists and ive directly seen lung scans, but theyve told me covid also is wrecking peoples brains, liver, kidney and arteries. I think we have a dark horse here and certainly there will be US hospitals trying to use the brain AI tech here going forwards

you guys have done about 300- 400%

BRH Covid summary
• https://www.kirkstall.com/ Respiratory models, QuasiVivo technology for research relating to COVID-19, assessment panel to decide which project proposals have most merit. This collaboration will enable research teams to respond quickly and use their skills to help understand how to treat this virus and the QuasiVivo system helps to minimise the need for animal trials.
• https://pharm2farm.myshopify.com/collections/hygiene medical grade alcohol hand sanitiser gel. In production to 2000 litres per day supplying NHS and care homes. Copper anti-viral Nanotech for PPE and filtration systems.
• https://www.phasefocus.com/ Phasefocus Holdings Limited - LiveCyte instrument to study the effect of viruses on living cells and the performance of drug candidates. Updated website with new video
• Sentinel Medical Limited - The science team is currently assessing how this aptamer based approach could be applied in a COVID-19 point-of-care detection instrument. Already have similar test for bladder cancer in the pipeline.
• Paraytec Limited ("Paraytec") (holding 100%) - NEXUS project with GSK, AZN, Fuji, Malvern, end user tests with major biopharmaceutical players have been looking at 'virus like particles' (VLPs) that are being used to deliver new gene therapy drugs and measuring protein aggregation. UV imaging systems. commercialisation phase of new instrument
Portfolio investments
Pyreos – Ventilator electronic parts https://pyreos.com/

Look what Hemo did from that low mcap - we are still only 7mill mcap

Looks like the top 5 holders here own 64%

Sentinel's technology will be used for reporting the presence of those cells. The science team is currently assessing how this approach could be applied in a COVID-19 point-of-care detection instrument.

this is going to go mental potentially

APTAMER GROUP PROCESS
Utilising our automation and parallel processing techniques, we can select high affinity and highly specific aptamers against the proteins of COVID-19.
APTAMER IMPACT
The benefit of the Aptamer approach is the ability to rapidly generate a reliable test – that specifically binds to the COVID-19 virus so the correct protocol (e.g. isolation, treatment) can be followed. The test would also show when people don’t have the virus and therefore allow healthcare providers to focus resources on those with greatest need.

Shortened development time for developing a rapid Point of Care COVID-19 test
At Aptamer Group, we utilise state-of-the-art in-vitro techniques to rapidly isolate nucleic acid sequences (aptamers), that are engineered to bind with high selectivity to a variety of targets. These include, but are not limited to, proteins, small molecules, whole cells and even whole organisms; therefore, we can employ aptamers in the fight against COVID-19.
Aptamers are commonly referred to as chemical antibodies; however, aptamers are quicker to develop and inexpensive to synthesize meaning we can develop tests, faster and more cost effectively, allowing us to get them into the hands of people who need them sooner!

Sentinal medical BRH investee - In addition to the ongoing trials with bladder cancer patient samples, Sentinel is currently awaiting the outcome of a joint grant application with the University of Sheffield, the Aptamer Group and the Leeds Teaching Hospitals NHS Trust for a project to look at aptamers as alternatives to antibodies for bladder cancer detection in urine. Here the aptamers will bind to the cancer cells and Sentinel's technology will be used for reporting the presence of those cells. The science team is currently assessing how this approach could be applied in a COVID-19 point-of-care detection instrument.

APTAMER IMPACT
The benefit of the Aptamer approach is the ability to rapidly generate a reliable test – that specifically binds to the COVID-19 virus so the correct protocol (e.g. isolation, treatment) can be followed. The test would also show when people don’t have the virus and therefore allow healthcare providers to focus resources on those with greatest need.

https://www.aptamergroup.co.uk/what-are-aptamers/aptamers-vs-antibodies/

exactly - you cant apply charts given the macro situation

if we land a test kit this is going to go crazy

tweeting get back to work with our scanners

WG 420 Body Temperature Detector & Sanitiser
A standalone non-contact unit which quickly and easily checks for above normal body temperature with immediate visual/audio feedback.
The hand sanitiser provides a focal point, with individuals and crowds being drawn to it as the culture of using hand sanitiser increases.
This affordable unit is self-contained and portable and can be rapidly set-up in temporary or fixed locations.

As many countries begin to ease restrictions on work and social movement, Westminster has the technology to make this transition as seamless as possible, helping your customers and employees to feel safe and secure.

WG 620 Fever Detection Camera
The WG 620 Fever Detection Camera enables accurate and fast fever screening of multiple individuals with no operator involvement.
This cost-effective device can be mounted on screens, tripods and stands to capture facial images and detect the body temperature of up to 5 people at the same time, from a range of up to 2 metres.
Full product description & brochure

im surprised this wasn't top riser today - maybe a late bloomer then

missed it., ffs

could be late bloomer

your reply

they haven't announced any partnerships just yet?